Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone919-237-5300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$24.18 million
Profitability
Miscellaneous
Employees353
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions
What is Aerie Pharmaceuticals' stock symbol?
Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."
How were Aerie Pharmaceuticals' earnings last quarter?
Aerie Pharmaceuticals Inc (NASDAQ:AERI) issued its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($0.91) by $0.13. The business had revenue of $10.85 million for the quarter, compared to analysts' expectations of $12.66 million. Aerie Pharmaceuticals had a negative return on equity of 93.96% and a negative net margin of 684.56%. View Aerie Pharmaceuticals' Earnings History.
When is Aerie Pharmaceuticals' next earnings date?
What price target have analysts set for AERI?
11 equities research analysts have issued 1 year price objectives for Aerie Pharmaceuticals' shares. Their forecasts range from $56.00 to $105.00. On average, they expect Aerie Pharmaceuticals' stock price to reach $78.00 in the next twelve months. This suggests a possible upside of 95.6% from the stock's current price. View Analyst Price Targets for Aerie Pharmaceuticals.
What is the consensus analysts' recommendation for Aerie Pharmaceuticals?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 1 sell rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aerie Pharmaceuticals.
What are Wall Street analysts saying about Aerie Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Aerie reported mixed results for the fourth quarter wherein loss was narrower than expected while sales missed estimates. Rhopressa sales missed estimates due to higher rebates. Nevertheless, the approval of the second drug, Rocklatan, a once-daily, quadruple-action fixed-dose combination of Rhopressa and Xalatan, has boosted the company’s portfolio and should propel sales in the coming quarters. We are also impressed with the company’s efforts to develop and boost its pipeline. However, shares have underperformed the industry in the past six months. While the glaucoma market holds potential, Aerie faces stiff competition from existing players and new ones like Vyzulta, among others." (5/16/2019)
- 2. Mizuho analysts commented, "We adjusted our 1Q19 revenue estimate for Rhopressa down but maintain our FY2019 net revenue estimate at the high-end of guidance. We expect Rhopressa Scripts to pick up around June driven by higher anticipated formulary coverage (Medicare Part D going from ~40% currently to ~70%+ in May – guided by management)." (4/21/2019)
Has Aerie Pharmaceuticals been receiving favorable news coverage?
News articles about AERI stock have trended extremely negative this week, according to InfoTrie. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aerie Pharmaceuticals earned a media sentiment score of -4.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.
Who are some of Aerie Pharmaceuticals' key competitors?
Some companies that are related to Aerie Pharmaceuticals include Neurocrine Biosciences (NBIX), bluebird bio (BLUE), argenx (ARGX), Spark Therapeutics (ONCE), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Iovance Biotherapeutics (IOVA), Denali Therapeutics (DNLI), Crispr Therapeutics (CRSP), Audentes Therapeutics (BOLD) and Regenxbio (RGNX).
What other stocks do shareholders of Aerie Pharmaceuticals own?
Who are Aerie Pharmaceuticals' key executives?
Aerie Pharmaceuticals' management team includes the folowing people:
- Dr. Vicente J. Anido Jr., CEO & Chairman (Age 66)
- Mr. Thomas A. Mitro, Pres & COO (Age 61)
- Dr. Casey C. Kopczynski, Co-Founder & Chief Scientific Officer (Age 58)
- Mr. Richard James Rubino CPA, CFO, Sec. & Treasurer (Age 61)
- Ms. Jessica Crespo CPA, Director of Accounting
Who are Aerie Pharmaceuticals' major shareholders?
Aerie Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (13.76%), BlackRock Inc. (6.59%), Jennison Associates LLC (2.93%), Pictet Asset Management Ltd. (1.76%), Daruma Capital Management LLC (1.63%) and FMR LLC (1.40%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Gerald D Cagle, Richard J Rubino, Thomas A Mitro and Vicente Anido Jr. View Institutional Ownership Trends for Aerie Pharmaceuticals.
Which major investors are selling Aerie Pharmaceuticals stock?
AERI stock was sold by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, FMR LLC, BlackRock Inc., Macquarie Group Ltd., Voya Investment Management LLC, Citigroup Inc., Essex Investment Management Co. LLC and Kornitzer Capital Management Inc. KS. Company insiders that have sold Aerie Pharmaceuticals company stock in the last year include Casey C Kopczynski, Richard J Rubino, Thomas A Mitro and Vicente Anido Jr. View Insider Buying and Selling for Aerie Pharmaceuticals.
Which major investors are buying Aerie Pharmaceuticals stock?
AERI stock was bought by a variety of institutional investors in the last quarter, including Daruma Capital Management LLC, Granite Investment Partners LLC, Pictet Asset Management Ltd., Frontier Capital Management Co. LLC, Jennison Associates LLC, Candriam Luxembourg S.C.A., Rice Hall James & Associates LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for Aerie Pharmaceuticals.
How do I buy shares of Aerie Pharmaceuticals?
Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aerie Pharmaceuticals' stock price today?
One share of AERI stock can currently be purchased for approximately $39.87.
How big of a company is Aerie Pharmaceuticals?
Aerie Pharmaceuticals has a market capitalization of $1.83 billion and generates $24.18 million in revenue each year. The company earns $-232,570,000.00 in net income (profit) each year or ($4.65) on an earnings per share basis. Aerie Pharmaceuticals employs 353 workers across the globe.
What is Aerie Pharmaceuticals' official website?
How can I contact Aerie Pharmaceuticals?
Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]
MarketBeat Community Rating for Aerie Pharmaceuticals (NASDAQ AERI)
MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote "Outperform" if you believe AERI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AERI will underperform the S&P 500 over the long term. You may vote once every thirty days.
